MAAQ vs. MEIP, ATHA, MRKR, SPRB, SLGL, GLYC, GOVX, AFMD, SYBX, and NRSN
Should you be buying Mana Capital Acquisition stock or one of its competitors? The main competitors of Mana Capital Acquisition include MEI Pharma (MEIP), Athira Pharma (ATHA), Marker Therapeutics (MRKR), Spruce Biosciences (SPRB), Sol-Gel Technologies (SLGL), GlycoMimetics (GLYC), GeoVax Labs (GOVX), Affimed (AFMD), Synlogic (SYBX), and NeuroSense Therapeutics (NRSN). These companies are all part of the "pharmaceutical products" industry.
Mana Capital Acquisition vs.
Mana Capital Acquisition (NASDAQ:MAAQ) and MEI Pharma (NASDAQ:MEIP) are both small-cap unclassified companies, but which is the superior investment? We will contrast the two companies based on the strength of their risk, earnings, valuation, media sentiment, analyst recommendations, institutional ownership, community ranking, profitability and dividends.
MEI Pharma has a consensus target price of $7.00, indicating a potential upside of 168.71%. Given MEI Pharma's stronger consensus rating and higher possible upside, analysts plainly believe MEI Pharma is more favorable than Mana Capital Acquisition.
MEI Pharma has higher revenue and earnings than Mana Capital Acquisition.
Mana Capital Acquisition's return on equity of 0.00% beat MEI Pharma's return on equity.
In the previous week, MEI Pharma had 1 more articles in the media than Mana Capital Acquisition. MarketBeat recorded 1 mentions for MEI Pharma and 0 mentions for Mana Capital Acquisition. Mana Capital Acquisition's average media sentiment score of 0.00 equaled MEI Pharma'saverage media sentiment score.
MEI Pharma received 411 more outperform votes than Mana Capital Acquisition when rated by MarketBeat users. However, 100.00% of users gave Mana Capital Acquisition an outperform vote while only 62.71% of users gave MEI Pharma an outperform vote.
68.4% of Mana Capital Acquisition shares are owned by institutional investors. Comparatively, 52.4% of MEI Pharma shares are owned by institutional investors. 3.1% of MEI Pharma shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.
Summary
MEI Pharma beats Mana Capital Acquisition on 6 of the 10 factors compared between the two stocks.
Get Mana Capital Acquisition News Delivered to You Automatically
Sign up to receive the latest news and ratings for MAAQ and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Mana Capital Acquisition Competitors List
Related Companies and Tools
This page (NASDAQ:MAAQ) was last updated on 2/22/2025 by MarketBeat.com Staff
Free MAAQ Stock Alerts